Device: adalimumab delivered in physiolis autoinjector (DrugBank: Adalimumab)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01163617 (ClinicalTrials.gov) | May 2010 | 4/5/2010 | The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients | A Multicenter, Randomized, Open-Label Study of the Injection Time and Usability of the Physiolis Syringe and Autoinjector in Injection-Experienced Rheumatoid Arthritis Patients | Rheumatoid Arthritis | Device: Adalimumab delivered in current syringe;Device: Adalimumab delivered in Physiolis syringe;Device: Adalimumab delivered in current autoinjector;Device: Adalimumab delivered in Physiolis autoinjector | AbbVie (prior sponsor, Abbott) | NULL | Completed | 18 Years | N/A | All | 85 | Phase 2 | United States |